Committed to Conquering Heart Failure

Focused on developing proprietary nanotherapeutics that target drugs to inflamed tissue in the heart. Cardiol’s nanoformulations of pharmaceutical cannabidiol (CTX01) and methotrexate (CTX02) offer the potential to prevent the chronic inflammatory processes that lead to the progression of heart failure.

Science & Technology

Proprietary nanotherapeutics designed to enhance the solubilization, pharmacokinetics, and targeting of drugs to sites of disease.

Therapeutic Targets

Cardiol is using nanotechnology to develop treatments that address the chronic inflammation underlying heart failure.

Research Collaboration

Collaborating with world-class researchers to leverage multidisciplinary expertise in drug delivery, formulation, nanotherapeutics, and heart failure.